Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial

Nigel Garrett, One Dintwe, Cynthia L. Monaco, Megan Jones, Kelly E. Seaton, Elizabeth Church, Nicole Grunenberg, Julia Hütter, Allan C. deCamp, Yunda Huang, Huiyin Lu, Philipp Mann, Samuel T. Robinson, Jack Heptinstall, Ryan L. Jensen, Giuseppe Pantaleo, S.-w Ding, Marguerite Koutsoukos, Mina C. Hosseinipour, Olivier Van Der Meeren, Peter B. Gilbert, Guido Ferrari, Erica Andersen‐Nissen, M. Juliana McElrath, Georgia D. Tomaras, Glenda Gray, Lawrence Corey, James G. Kublin, on behalf of the Hvtn 108 and Hvtn 111 Study TeamsJAIDS 2024 · DOI

TL;DR

This study evaluated a novel DNA/protein HIV vaccine regimen using different adjuvants (MF59 vs. AS01B) and dosing strategies in a Phase 1/2a trial. The AS01B-adjuvanted co-administration regimen showed the most promising results, inducing robust and durable antibody responses and stronger CD4+ T-cell responses, suggesting it's a strong candidate for further development.

What Problem Does This Paper Address?

Despite significant global efforts, an effective HIV vaccine remains elusive, with the RV144 trial being the only one to show partial efficacy against acquisition to date. The urgent need for a vaccine drives research into novel strategies, particularly those targeting prevalent HIV strains in regions with high infection rates. This paper addresses the challenge of developing a more effective HIV vaccine by exploring a combination approach: a DNA prime followed by protein boosts, or co-administration of DNA and protein, using different adjuvants (MF59 and AS01B) and varying protein doses. The goal is to identify a regimen that elicits strong, durable, and protective immune responses, building on lessons learned from previous trials like RV144 and HVTN100.

Methods

This was a randomized, double-blind, placebo-controlled, Phase 1/2a trial (HVTN108) conducted across multiple sites in the US and South Africa. A subset of participants from a related trial (HVTN111) with identical regimens were included for immunogenicity analysis. Participants were assigned to one of seven intervention arms or a placebo group. The study compared different vaccination strategies:

  • Prime-Boost: DNA priming followed by DNA/protein/adjuvant boosts.
  • Co-administration: Simultaneous administration of DNA, protein, and adjuvant.
  • Protein-only: Low-dose protein with AS01B adjuvant.

The study evaluated two main HIV clade C envelope proteins (gp120 and gp140) and two adjuvants: MF59 and AS01B. Safety was assessed through reactogenicity and adverse event monitoring. Immunogenicity was measured by:

  • Binding Antibody Multiplex Assay: To quantify IgG and IgG3 responses to various HIV antigens.
  • ADCP and ADCC Assays: To assess antibody-dependent cellular functions.
  • Intracellular Cytokine Staining (ICS) Assay: To measure CD4+ T-cell responses (IFN-γ, IL-2, CD154).

Statistical analyses compared response rates and magnitudes between groups.

Datasets

The study utilized data from 400 participants (334 from HVTN108 and 66 from HVTN111) who were HIV-negative adults aged 18-40. The data collected included demographic information, safety data (reactogenicity and adverse events), and immunogenicity data from blood samples collected at specific time points post-vaccination. No new benchmarks were introduced; the study focused on evaluating existing vaccine components and strategies.

Key Insights and Ideas

  • AS01B's Potency: The AS01B adjuvant consistently demonstrated superior performance compared to MF59 across various immune response measures, particularly in eliciting stronger and more durable antibody and CD4+ T-cell responses. This highlights AS01B as a promising adjuvant for future HIV vaccine development.
  • Co-administration Advantage: The co-administration strategy, especially when combined with AS01B, led to more robust and durable antibody responses compared to prime-boost regimens. This suggests that delivering all components simultaneously might be a more effective way to prime the immune system.
  • Lower Dose Efficacy: Surprisingly, the lower dose of the protein component (20 µg) in some AS01B-adjuvanted regimens elicited immune responses comparable to, or even better than, the higher dose (100 µg). This is a crucial finding for potential cost-effectiveness and reduced reactogenicity in future vaccine development.
  • Fc Effector Functions Matter: The study provided insights into the role of Fc effector functions (like ADCP and ADCC) in vaccine responses, suggesting they may be important for HIV prevention, even in the absence of strong neutralizing antibodies. AS01B's influence on these functions is a key area of interest.
  • CD8+ T-cell Response Limitation: Similar to many previous HIV vaccine trials, this study observed very few CD8+ T-cell responses, indicating that current vaccine strategies may need to be re-evaluated to effectively engage this arm of the immune system for HIV prevention.

Key Results

  • Safety: All vaccine regimens were generally well tolerated. AS01B-adjuvanted groups reported more local and systemic reactogenicity events, but these were mostly mild to moderate and self-limiting. No grade 4 local reactogenicity complications or serious adverse events were reported.
  • Humoral Immunity (Antibodies): All intervention groups showed high IgG response rates (>89%) and magnitudes to HIV-1 Env gp120 and gp140 proteins. AS01B-adjuvanted groups approached 100% response rates. Antibody responses were more durable in AS01B-adjuvanted co-administration groups.
  • Cellular Immunity (T-cells): AS01B-adjuvanted regimens elicited stronger CD4+ T-cell responses, which persisted for at least 6 months after the last vaccination.
  • Functional Immunity: AS01B-adjuvanted co-administration groups showed higher phagocytosis scores (ADCP) compared to MF59-adjuvanted groups.

Limitations and Future Work

  • Phase 1/2a Trial: As a Phase 1/2a trial, this study did not assess HIV infection endpoints, meaning the direct protective efficacy of these regimens remains unknown. Larger trials are needed to determine if the observed immune responses translate into protection.
  • Co-administration vs. Prime-Boost Comparison Nuance: While comparisons were made, co-administration participants received three protein doses, while prime-boost participants received two. This difference in total protein exposure could influence the interpretation of some results.
  • CD8+ T-cell Response: The limited induction of CD8+ T-cell responses suggests that new strategies may be needed to activate this crucial immune cell type for effective HIV prevention.
  • Future Work: The authors suggest that the AS01B-adjuvanted co-administration regimen, particularly with the lower protein dose, warrants further evaluation in larger efficacy trials due to its robust and durable immune responses. Further research into the role of Fc effector functions and strategies to enhance CD8+ T-cell responses is also recommended.

Summary updated

Abstract

The vaccine regimens were generally well tolerated. Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120 elicited the strongest humoral responses; AS01B-adjuvanted regimens elicited stronger CD4+ T-cell responses, justifying further evaluation.ClinicalTrials.gov registration: NCT02915016, registered 26 September 2016.
BibTeX
@inproceedings{garrett2024safety,
  author = {Nigel Garrett and One Dintwe and Cynthia L. Monaco and Megan Jones and Kelly E. Seaton and Elizabeth Church and Nicole Grunenberg and Julia Hütter and Allan C. deCamp and Yunda Huang and Huiyin Lu and Philipp Mann and Samuel T. Robinson and Jack Heptinstall and Ryan L. Jensen and Giuseppe Pantaleo and S.-W Ding and Marguerite Koutsoukos and Mina C. Hosseinipour and Olivier Van Der Meeren and Peter B. Gilbert and Guido Ferrari and Erica Andersen‐Nissen and M. Juliana McElrath and Georgia D. Tomaras and Glenda Gray and Lawrence Corey and James G. Kublin and on behalf of the HVTN 108 and HVTN 111 Study Teams},
  title = {{Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial}},
  booktitle = {JAIDS},
  year = {2024},
  doi = {10.1097/qai.0000000000003438},
}
Figure